Logo

GlaxoSmithKline Will Use Beyond Genomics Platform

Dec 10, 2002

NEW YORK, Dec. 10-GlaxoSmithKline will use Beyond Genomics' systems biology platform to describe disease pathways and identify disease and drug response markers, the company said in a statement today.

 

The deal is an "evaluation agreement." Financial details and specifics of the agreement were not revealed.

 

Beyond Genomics, based in Waltham, Mass., combines proteomic and metabolomic analysis with pattern recognition and data mining software for a systems approach to drug discovery and development.

 

For further details, see the press release

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.